Ikarian Capital’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.91M Buy
86,761
+38,900
+81% +$4.17M 0.7% 37
2026
Q2
$4.43M Buy
+47,861
New +$2.96M 0.48% 61
2025
Q2
– Sell
-5,908
Closed -$215K – 172
2025
Q1
$215K Hold
5,908
– – 0.03% 136
2024
Q4
$130K Buy
+5,908
New +$99.1K 0.02% 153

Other funds holding MNPR

Ikarian Capital's MNPR Position: Q3 2026 in Review

Ikarian Capital increased its Monopar Therapeutics (MNPR) stake by 81% in Q3 2026, buying an estimated $4.17M and bringing the position to 86,761 shares worth $6.91M. The position accounts for 0.7% of the portfolio, ranked #37.

Ikarian Capital first reported a position in MNPR in Q4 2024 and has held it in 4 quarters since. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Ikarian Capital held 86,761 shares of Monopar Therapeutics worth $6.91M as of Q3 2026.
  • Ikarian Capital bought 38,900 Monopar Therapeutics shares in Q3 2026, an estimated $4.17M.
  • Monopar Therapeutics made up 0.7% of Ikarian Capital's portfolio in Q3 2026, its #37 holding.
  • Ikarian Capital first reported a position in Monopar Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.